San Antonio

Innovative App Together By Renee Aids Patients Amidst Widespread U.S. Drug Shortage Crisis

AI Assisted Icon
Published on May 29, 2024
Innovative App Together By Renee Aids Patients Amidst Widespread U.S. Drug Shortage CrisisSource: Unsplash/ Andrej Lišakov

In the midst of a dire nationwide drug shortage, an innovative AI-driven app promises to guide patients to the pharmacies that can fill their prescriptions. GLP-1 drugs, critical for weight loss and conditions like diabetes and heart disease, are at the forefront of this shortage. Pharmacies are scrambling, with some patients left in the lurch as they seek their essential medications.

Renee Dua, founder of the health care platform Together By Renee, emphasized in an interview with KENS 5 the app's utility. Patients can snap a photo of their pill bottle and log their vitals using the app, which then hunts down available stock in local pharmacies. Despite the app's advances, it battles an uphill war against an opaque crisis where 60% of drug shortage reasons remain unexplained or undisclosed, according to a nationwide investigation covered in 2023.

The app "Together By Renee" steps in to bridge the troubling gap between supply and demand. "More and more people are able to use them for obesity and management of diabetes. We also have data that people who use GLP ones are having improvement in heart conditions and kidney conditions. So of course everyone is prescribing them," Renee Dua told KENS 5. Dua's app thus serves the critical role of navigating patients to the meds they require urgently.

With the inception of "Together By Renee," customers can now avoid the risk of missing doses—knowingly trapped in a conundrum where the drug industry can't catch up to the soaring demands. "There is such a shortage because so many people using them, and the pharmaceutical companies cannot keep up with supply," Dua added. This free app provides much-needed assistance, striving to ensure that patients maintain their health regimens amidst the chaos of shortages.